Skip to main content
SpringerLink
Log in

Barrett’s Esophagus: Diagnosis and Management

  • Chapter
Esophageal Cancer

  • 1613 Accesses

Abstract

Esophageal adenocarcinoma (EAC) is one of the most rapidly increasing cancers in developed countries. EAC is thought to always or near always arise from a specialized intestinal metaplasia in the esophagus, called Barrett’s esophagus (BE), which forms in the lower esophagus in response to chronic acid reflux injury [1]. Barrett’s esophagus occurs in 1–6.4 % of the US population and is the strongest risk factor for esophageal adenocarcinoma (EAC) [2]. As such, people with BE are placed in surveillance programs with the intent to decrease EAC-associated mortality. Unfortunately, despite years of study of BE and EAC, it is still controversial whether current BE surveillance programs effectively decrease mortality from EAC. The controversy likely stems from low sensitivity methods for identifying people with BE, the modest accuracy of current surveillance methods to identify people with BE at increased risk of EAC, and the morbidity of historical treatments for high-grade dysplasia and EAC. Recent advances have been made or are being made that address all these issues; thus, BE continues to be a promising target for screening and surveillance [3, 4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Paulson TG, Reid BJ. Focus on Barrett’s esophagus and esophageal adenocarcinoma. Cancer Cell. 2004;6(1):11–6. doi:10.1016/j.ccr.2004.06.021.

  2. Kadri S, Lao-Sirieix P, Fitzgerald RC. Developing a nonendoscopic screening test for Barrett’s esophagus. Biomark Med. 2011;5(3):397–404. doi:10.2217/bmm.11.40.

  3. Verbeek RE, Leenders M, Ten Kate FJ, van Hillegersberg R, Vleggaar FP, van Baal JW, van Oijen MG, Siersema PD. Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol. 2014;109(8):1215–22. doi:10.1038/ajg.2014.156.

  4. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23(12):3155–62. doi:10.1093/annonc/mds181.

  5. American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140(3):1084–91. doi:10.1053/j.gastro.2011.01.030; 10.1053/j.gastro.2011.01.030.

  6. ASGE Standards of Practice Committee, Evans JA, Early DS, Fukami N, Ben-Menachem T, Chandrasekhara V, Chathadi KV, Decker GA, Fanelli RD, Fisher DA, Foley KQ, Hwang JH, Jain R, Jue TL, Khan KM, Lightdale J, Malpas PM, Maple JT, Pasha SF, Saltzman JR, Sharaf RN, Shergill A, Dominitz JA, Cash BD. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76(6):1087–94. doi:10.1016/j.gie.2012.08.004; 10.1016/j.gie.2012.08.004

  7. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, Patel P, Kaye PV, Sanders S, O’Donovan M, Bird-Lieberman E, Bhandari P, Jankowski JA, Attwood S, Parsons SL, Loft D, Lagergren J, Moayyedi P, Lyratzopoulos G, de Caestecker J, British Society of G. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42. doi:10.1136/gutjnl-2013-305372.

  8. Takubo K, Vieth M, Aida J, Sawabe M, Kumagai Y, Hoshihara Y, Arai T. Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett’s adenocarcinoma, the definition of Barrett’s esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. Digestion. 2009;80(4):248–57. doi:10.1159/000235923.

  9. Kusano C, Kaltenbach T, Shimazu T, Soetikno R, Gotoda T. Can Western endoscopists identify the end of the lower esophageal palisade vessels as a landmark of esophagogastric junction? J Gastroenterol. 2009;44(8):842–6. doi:10.1007/s00535-009-0083-1.

  10. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. New Engl J Med. 1976;295(9):476–80. doi:10.1056/NEJM197608262950904.

  11. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103(13):1049–57. doi:10.1093/jnci/djr203.

  12. Westerhoff M, Hovan L, Lee C, Hart J. Effects of dropping the requirement for goblet cells from the diagnosis of Barrett’s esophagus. Clin Gastroenterol Hepatol. 2012;10(11):1232–6. doi:10.1016/j.cgh.2012.05.013.

  13. Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus. 2007;20(1):36–41. doi:DES638 [pii].

    Google Scholar 

  14. Gilbert EW, Luna RA, Harrison VL, Hunter JG. Barrett’s esophagus: a review of the literature. J Gastrointest Surg. 2011;15(5):708–18. doi:10.1007/s11605-011-1485-y.

  15. Barrett NR. Chronic peptic ulcer of the oesophagus and ‘oesophagitis’. Br J Surg. 1950;38(150):175–82.

    Article  CAS  PubMed  Google Scholar 

  16. Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA. 2013;310(6):627–36. doi:10.1001/jama.2013.226450.

  17. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett’s oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10(2):87–101. doi:10.1038/nrc2773.

  18. Dulai GS, Shekelle PG, Jensen DM, Spiegel BM, Chen J, Oh D, Kahn KL. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett’s cohort. Am J Gastroenterol. 2005;100(4):775–83. doi:AJG41300 [pii].

    Google Scholar 

  19. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4(5):566–72. doi:S1542-3565(06)00227-8 [pii].

    Google Scholar 

  20. Bhat SK, McManus DT, Coleman HG, Johnston BT, Cardwell CR, McMenamin U, Bannon F, Hicks B, Kennedy G, Gavin AT, Murray LJ. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut. 2014. doi:10.1136/gutjnl-2013-305506.

  21. Balasubramanian G, Singh M, Gupta N, Gaddam S, Giacchino M, Wani SB, Moloney B, Higbee AD, Rastogi A, Bansal A, Sharma P. Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am J Gastroenterol. 2012;107(11):1655–61. doi:10.1038/ajg.2012.299.

  22. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 1994;344(8936):1533–6. doi:S0140-6736(94)90349-2 [pii].

    Google Scholar 

  23. Connor MJ, Weston AP, Mayo MS, Sharma P. The prevalence of Barrett’s esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population. Dig Dis Sci. 2004;49(6):920–4.

    Article  PubMed  Google Scholar 

  24. Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, Vasudeva RS, Dunne D, Rahmani EY, Helper DJ. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003; 125(6):1670–7. doi:S0016508503015233 [pii].

    Google Scholar 

  25. Rubenstein JH, Morgenstern H, Appelman H, Scheiman J, Schoenfeld P, McMahon LF, Jr., Metko V, Near E, Kellenberg J, Kalish T, Inadomi JM. Prediction of Barrett’s esophagus among men. Am J Gastroenterol. 2013;108(3):353–62. doi:10.1038/ajg.2012.446.

  26. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agreus L. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129(6):1825–31. doi:S0016-5085(05)01771-3 [pii].

    Google Scholar 

  27. Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, Farahmand BY, Winchester CC, Roda E, Bazzoli F. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354–9. doi:10.1136/gut.2007.145177.

  28. Ronkainen J, Talley NJ, Storskrubb T, Johansson SE, Lind T, Vieth M, Agreus L, Aro P. Erosive esophagitis is a risk factor for Barrett’s esophagus: a community-based endoscopic follow-up study. The American Journal of Gastroenterology. 2011;106(11):1946–52. doi:10.1038/ajg.2011.326.

  29. Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett’s esophagus. Am J Gastroenterol. 2010;105(8):1729, 1730-1727; quiz 1738. doi:10.1038/ajg.2010.194.

  30. Spechler SJ, Souza RF. Barrett’s esophagus. New Engl J Med. 2014;371(9):836–45. doi:10.1056/NEJMra1314704.

  31. de Jonge PJ, van Blankenstein M, Grady WM, Kuipers EJ. Barrett’s oesophagus: epidemiology, cancer risk and implications for management. Gut. 2014;63(1):191–202. doi:10.1136/gutjnl-2013-305490.

  32. Rubenstein JH. Risk factors for Barrett’s esophagus. Curr Opin Gastroenterol. 2014;30(4):408–14. doi:10.1097/MOG.0000000000000084.

  33. Leggett CL, Gorospe EC, Calvin AD, Harmsen WS, Zinsmeister AR, Caples S, Somers VK, Dunagan K, Lutzke L, Wang KK, Iyer PG. Obstructive sleep apnea is a risk factor for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014;12(4):583–88.e581. doi:10.1016/j.cgh.2013.08.043.

  34. Anderson LA, Watson RG, Murphy SJ, Johnston BT, Comber H, Mc Guigan J, Reynolds JV, Murray LJ. Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13(10):1585–94.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Rumore G, Quesenberry C, Buffler P, Parsonnet J. Helicobacter pylori infection and the risk of Barrett’s oesophagus: a community-based study. Gut. 2008;57(6):727–733. doi:gut.2007.132068 [pii].

    Google Scholar 

  36. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. New Engl J Med. 2011;365(15):1375–83. doi:10.1056/NEJMoa1103042.

  37. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59(8):1030–6. doi:10.1136/gut.2009.176701.

  38. Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, Bohmer C, Mallant-Hent RC, van Oijen A, Naber AH, Scholten P, Busch OR, Blaauwgeers HG, Meijer GA, Bergman JJ. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523–30. doi:10.1038/ajg.2010.171.

  39. Wani S, Falk GW, Post J, Yerian L, Hall M, Wang A, Gupta N, Gaddam S, Singh M, Singh V, Chuang KY, Boolchand V, Gavini H, Kuczynski J, Sud P, Bansal A, Rastogi A, Mathur SC, Young P, Cash B, Goldblum J, Lieberman DA, Sampliner RE, Sharma P. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141(4):1179–86, 1186.e1171. doi:10.1053/j.gastro.2011.06.055.

  40. Thota PN, Lee HJ, Goldblum JR, Liu X, Sanaka MR, Gohel T, Kanadiya M, Lopez R. Risk stratification of patients with Barrett’s esophagus and low-grade dysplasia or indefinite for dysplasia. Clin Gastroenterol Hepatol. 2014. doi:S1542-3565(14)01095-7 [pii].

    Google Scholar 

  41. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67(3):394–8. doi:S0016-5107(07)02372-3 [pii].

    Google Scholar 

  42. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O’Connell S, Seidel UJ, Sonnenberg A. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120(7):1607–19.

    Article  CAS  PubMed  Google Scholar 

  43. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, Anderson MA, Petterson TM, Burgart LJ. Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120(7):1630–9.

    Article  CAS  PubMed  Google Scholar 

  44. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett’s high-grade dysplasia. Am J Gastroenterol. 2000;95(8):1888–93. doi:S0002-9270(00)01026-1 [pii].

    Google Scholar 

  45. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett’s esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96(11):3071–83. doi:S0002-9270(01)03823-0 [pii].

    Google Scholar 

  46. Cook MB, Corley DA, Murray LJ, Liao LM, Kamangar F, Ye W, Gammon MD, Risch HA, Casson AG, Freedman ND, Chow WH, Wu AH, Bernstein L, Nyren O, Pandeya N, Whiteman DC, Vaughan TL. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON). PloS One. 2014;9(7):e103508. doi:10.1371/journal.pone.0103508.

  47. Gaddam S, Singh M, Balasubramanian G, Thota P, Gupta N, Wani S, Higbee AD, Mathur SC, Horwhat JD, Rastogi A, Young PE, Cash BD, Bansal A, Vargo JJ, Falk GW, Lieberman DA, Sampliner RE, Sharma P. Persistence of nondysplastic Barrett’s esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology. 2013;145(3):548–53.e541. doi:10.1053/j.gastro.2013.05.040.

  48. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthusamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ. Radiofrequency ablation in Barrett’s esophagus with dysplasia. New Engl J Med. 2009;360(22):2277–88. doi:10.1056/NEJMoa0808145; 10.1056/NEJMoa0808145.

  49. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett’s esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology. 1992;102(4 Pt 1):1212–9. doi:S0016508592001537 [pii].

    Google Scholar 

  50. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalosvki M. Prospective long-term endoscopic and histological follow-up of short segment Barrett’s esophagus: comparison with traditional long segment Barrett’s esophagus. Am J Gastroenterol. 1997;92(3):407–13.

    CAS  PubMed  Google Scholar 

  51. Horwhat JD, Baroni D, Maydonovitch C, Osgard E, Ormseth E, Rueda-Pedraza E, Lee HJ, Hirota WK, Wong RK. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol. 2007;102(3):497–506. doi:AJG994 [pii].

    Google Scholar 

  52. Oelschlager BK, Barreca M, Chang L, Oleynikov D, Pellegrini CA. Clinical and pathologic response of Barrett’s esophagus to laparoscopic antireflux surgery. Ann Surg. 2003;238(4):458–64; discussion 464–456. doi:10.1097/01.sla.0000090443.97693.c3.

  53. Varghese S, Lao-Sirieix P, Fitzgerald RC. Identification and clinical implementation of biomarkers for Barrett’s esophagus. Gastroenterology. 2012;142(3):435–41.e432. doi:10.1053/j.gastro.2012.01.013.

  54. Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett’s esophagus compared with the general population: a population-based cohort study. Gastroenterology. 2013;144(7):1375–83, 1383.e1371. doi:10.1053/j.gastro.2013.02.050.

  55. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4(2):e67. doi:06-PLME-RA-0387R2 [pii].

    Google Scholar 

  56. Bird-Lieberman EL, Dunn JM, Coleman HG, Lao-Sirieix P, Oukrif D, Moore CE, Varghese S, Johnston BT, Arthur K, McManus DT, Novelli MR, O’Donovan M, Cardwell CR, Lovat LB, Murray LJ, Fitzgerald RC. Population-based study reveals new risk-stratification biomarker panel for Barrett’s esophagus. Gastroenterology. 2012;143(4):927–35.e923. doi:10.1053/j.gastro.2012.06.041.

  57. Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJ, Krishnadath KK. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett’s esophagus. Cancer Epidemiol Biomark Prev. 2008;17(6):1380–5. doi:10.1158/1055-9965.EPI-07-2734.

  58. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38(4):468–73. doi:ng1768 [pii].

    Google Scholar 

  59. Kaz AM, Grady WM. Epigenetic biomarkers in esophageal cancer. Cancer Lett. 2014;342(2):193–9. doi:10.1016/j.canlet.2012.02.036.

  60. Revilla-Nuin B, Parrilla P, Lozano JJ, de Haro LF, Ortiz A, Martinez C, Munitiz V, de Angulo DR, Bermejo J, Molina J, Cayuela ML, Yelamos J. Predictive value of MicroRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann Surg. 2013;257(5):886–93. doi:10.1097/SLA.0b013e31826ddba6.

  61. Kadri SR, Lao-Sirieix P, O’Donovan M, Debiram I, Das M, Blazeby JM, Emery J, Boussioutas A, Morris H, Walter FM, Pharoah P, Hardwick RH, Fitzgerald RC. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ (Clinical research ed). 2010;341:c4372. doi:10.1136/bmj.c4372.

  62. Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology. 2013;144(1):62–73.e66. doi:10.1053/j.gastro.2012.09.060.

  63. Alvarez Herrero L, Curvers WL, van Vilsteren FG, Wolfsen H, Ragunath K, Wong Kee Song LM, Mallant-Hent RC, van Oijen A, Scholten P, Schoon EJ, Schenk EB, Weusten BL, Bergman JG. Validation of the Prague C&M classification of Barrett’s esophagus in clinical practice. Endoscopy. 2013;45(11):876–82. doi:10.1055/s-0033-1344952.

  64. Vahabzadeh B, Seetharam AB, Cook MB, Wani S, Rastogi A, Bansal A, Early DS, Sharma P. Validation of the Prague C & M criteria for the endoscopic grading of Barrett’s esophagus by gastroenterology trainees: a multicenter study. Gastrointest Endosc. 2012;75(2):236–41. doi:10.1016/j.gie.2011.09.017.

  65. Montgomery E, Bronner MP, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Washington K, Goldblum JR. Are ulcers a marker for invasive carcinoma in Barrett’s esophagus? Data from a diagnostic variability study with clinical follow-up. Am J Gastroenterol. 2002;97(1):27–31. doi:10.1111/j.1572-0241.2002.05420.x.

  66. Kara MA, Peters FP, Rosmolen WD, Krishnadath KK, ten Kate FJ, Fockens P, Bergman JJ. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37(10):929–36. doi:10.1055/s-2005-870433.

  67. Thomas T, Gilbert D, Kaye PV, Penman I, Aithal GP, Ragunath K. High-resolution endoscopy and endoscopic ultrasound for evaluation of early neoplasia in Barrett’s esophagus. Surg Endosc. 2010;24(5):1110–6. doi:10.1007/s00464-009-0737-3.

  68. Pech O, Gossner L, Manner H, May A, Rabenstein T, Behrens A, Berres M, Huijsmans J, Vieth M, Stolte M, Ell C. Prospective evaluation of the macroscopic types and location of early Barrett’s neoplasia in 380 lesions. Endoscopy. 2007;39(7):588–93. doi:10.1055/s-2007-966363.

  69. Moss A, Bourke MJ, Hourigan LF, Gupta S, Williams SJ, Tran K, Swan MP, Hopper AD, Kwan V, Bailey AA. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol. 2010;105(6):1276–83. doi:10.1038/ajg.2010.1; 10.1038/ajg.2010.1.

  70. Mino-Kenudson M, Hull MJ, Brown I, Muzikansky A, Srivastava A, Glickman J, Park DY, Zuckerberg L, Misdraji J, Odze RD, Lauwers GY. EMR for Barrett’s esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc. 2007;66(4):660–6; quiz 767, 769. doi:S0016-5107(07)00405-1 [pii].

    Google Scholar 

  71. Mino-Kenudson M, Brugge WR, Puricelli WP, Nakatsuka LN, Nishioka NS, Zukerberg LR, Misdraji J, Lauwers GY. Management of superficial Barrett’s epithelium-related neoplasms by endoscopic mucosal resection: clinicopathologic analysis of 27 cases. Am J Surg Pathol. 2005;29(5):680–6. doi:00000478-200505000-00016 [pii].

    Google Scholar 

  72. Mandal RV, Forcione DG, Brugge WR, Nishioka NS, Mino-Kenudson M, Lauwers GY. Effect of tumor characteristics and duplication of the muscularis mucosae on the endoscopic staging of superficial Barrett esophagus-related neoplasia. Am J Surg Pathol. 2009;33(4):620–5. doi:10.1097/PAS.0b013e31818d632f.

  73. Wani S, Abrams J, Edmundowicz SA, Gaddam S, Hovis CE, Green D, Gupta N, Higbee A, Bansal A, Rastogi A, Early D, Lightdale CJ, Sharma P. Endoscopic mucosal resection results in change of histologic diagnosis in Barrett’s esophagus patients with visible and flat neoplasia: a multicenter cohort study. Digest Dis Sci. 2013;58(6):1703–9. doi:10.1007/s10620-013-2689-7.

  74. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47(2):251–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol. 2000;95(12):3383–7. doi:S0002-9270(00)02141-9 [pii].

    Google Scholar 

  76. Lim CH, Treanor D, Dixon MF, Axon AT. Low-grade dysplasia in Barrett’s esophagus has a high risk of progression. Endoscopy. 2007;39(7):581–7. doi:10.1055/s-2007-966592.

  77. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, Shyr Y, Washington K. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32(4):368–78. doi:S0046-8177(01)91787-3 [pii]

    Google Scholar 

  78. Paul S, Altorki N. Outcomes in the management of esophageal cancer. J Surg Oncol. 2014. doi:10.1002/jso.23759.

  79. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett’s oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther. 2004;20(6):637–43. doi:10.1111/j.1365-2036.2004.02127.x.

  80. Kastelein F, Spaander MC, Steyerberg EW, Biermann K, Valkhoff VE, Kuipers EJ, Bruno MJ, ProBar Study G. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013;11(4):382–8. doi:10.1016/j.cgh.2012.11.014.

  81. Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014;39(9):984–91. doi:10.1111/apt.12693.

  82. Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett’s esophagus with and without dysplasia. Dis Esophagus. 2007;20(6):516–22. doi:DES728 [pii].

    Google Scholar 

  83. Akiyama J, Marcus SN, Triadafilopoulos G. Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett’s esophagus. Digest Dis Sci. 2012;57(10):2625–32. doi:10.1007/s10620-012-2313-2.

  84. Jovov B, Shaheen NJ, Orlando GS, Djukic Z, Orlando RC. Defective barrier function in neosquamous epithelium. Am J Gastroenterol. 2013;108(3):386–91. doi:10.1038/ajg.2012.440; 10.1038/ajg.2012.440.

  85. Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ, Probar-Study G. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett’s esophagus. Gastroenterology. 2011;141(6):2000–8; quiz e2013-2004. doi:10.1053/j.gastro.2011.08.036.

  86. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. 2010;138(7):2260–6. doi:10.1053/j.gastro.2010.02.045.

  87. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol. 2005;6(12):945–52. doi:S1470-2045(05)70431-9 [pii].

    Google Scholar 

  88. Khalaf N, Nguyen T, Ramsey D, El-Serag HB. Nonsteroidal anti-inflammatory drugs and the risk of Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014. doi:S1542-3565(14)00633-8 [pii].

    Google Scholar 

  89. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, Vlahcevic ZR, Young R, Williford W. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285(18):2331–8. doi:joc02260 [pii].

    Google Scholar 

  90. Tran T, Spechler SJ, Richardson P, El-Serag HB. Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs cohort study. Am J Gastroenterol. 2005;100(5):1002–8. doi:AJG41007 [pii].

    Google Scholar 

  91. Dunbar KB, Spechler SJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett’s esophagus: a systematic review. Am J Gastroenterol. 2012;107(6):850–62; quiz 863. doi:10.1038/ajg.2012.78; 10.1038/ajg.2012.78.

  92. Konda VJ, Gonzalez Haba Ruiz M, Koons A, Hart J, Xiao SY, Siddiqui UD, Ferguson MK, Posner M, Patti MG, Waxman I. Complete endoscopic mucosal resection is effective and durable treatment for Barrett’s-associated neoplasia. Clin Gastroenterol Hepatol. 2014. doi:S1542-3565(14)00597-7 [pii].

    Google Scholar 

  93. Chung A, Bourke MJ, Hourigan LF, Lim G, Moss A, Williams SJ, McLeod D, Fanning S, Kariyawasam V, Byth K. Complete Barrett’s excision by stepwise endoscopic resection in short-segment disease: long term outcomes and predictors of stricture. Endoscopy. 2011;43(12):1025–32. doi:10.1055/s-0030-1257049; 10.1055/s-0030-1257049.

  94. Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Prac J Am Gastroenterol Assoc. 2013;11(10):1245–55. doi:10.1016/j.cgh.2013.03.039.

  95. Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, Sharma VK, Eisen GM, Fennerty MB, Hunter JG, Bronner MP, Goldblum JR, Bennett AE, Mashimo H, Rothstein RI, Gordon SR, Edmundowicz SA, Madanick RD, Peery AF, Muthusamy VR, Chang KJ, Kimmey MB, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Dumot JA, Falk GW, Galanko JA, Jobe BA, Hawes RH, Hoffman BJ, Sharma P, Chak A, Lightdale CJ. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141(2):460–8. doi:10.1053/j.gastro.2011.04.061; 10.1053/j.gastro.2011.04.061.

  96. Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2012;143(3):567–575. doi:10.1053/j.gastro.2012.05.010.

  97. Gordon LG, Mayne GC, Hirst NG, Bright T, Whiteman DC, Australian Cancer Study Clinical Follow-Up S, Watson DI. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc. 2014;79(2):242–56.e246. doi:10.1016/j.gie.2013.07.046.

  98. Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145(2):312–9.e311. doi:10.1053/j.gastro.2013.05.004.

  99. Falk GW, Ours TM, Richter JE. Practice patterns for surveillance of Barrett’s esophagus in the United States. Gastrointest Endosc. 2000;52(2):197–203. doi:S0016-5107(00)81282-1 [pii].

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Gastroenterology, University of Washington School of Medicine, Seattle, WA, USA

    Adam Templeton, Andrew Kaz & William M. Grady MD

  2. Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., D4-100, Seattle, WA, 98109, USA

    Andrew Kaz & William M. Grady MD

  3. G astroenterology Section, VA Puget Sound Healthcare System, Seattle, WA, USA

    Andrew Kaz

Authors
  1. Adam Templeton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Kaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William M. Grady MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William M. Grady MD .

Editor information

Editors and Affiliations

  1. Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA

    Nabil F. Saba

  2. Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA

    Bassel F. El-Rayes

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Templeton, A., Kaz, A., Grady, W.M. (2015). Barrett’s Esophagus: Diagnosis and Management. In: Saba, N., El-Rayes, B. (eds) Esophageal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-20068-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20068-2_4

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-20067-5

  • Online ISBN: 978-3-319-20068-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation